| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $3,140,374 ) |
| | 2024 | 2024 | PHARMAIN CORPORATION | 11812 N CREEK PKWY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 001 | 5 | NIH | 9/17/2024 | $2,145,275 |
| | 2024 | 2024 | PHARMAIN CORPORATION | 11812 N CREEK PKWY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44CA278570 | Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human | 000 | 2 | NIH | 8/16/2024 | $995,099 |
| | 2024 | 2022 | PHARMAIN CORPORATION | 11812 N CREEK PKWY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44HL156295 | CMC of Peptide Formulation for the Treatment of ARDS | 000 | 1 | NIH | 3/21/2024 | $0 |
| | 2024 | 2022 | PHARMAIN CORPORATION | 11812 N CREEK PKWY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 000 | 4 | NIH | 2/21/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,962,840 ) |
| | 2023 | 2023 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44HL156295 | CMC of Peptide Formulation for the Treatment of ARDS | 001 | 2 | NIH | 6/9/2023 | $967,740 |
| | 2023 | 2023 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44CA278570 | Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human | 000 | 1 | NIH | 9/19/2023 | $995,100 |
| | 2023 | 2022 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44HL156295 | CMC of Peptide Formulation for the Treatment of ARDS | 000 | 1 | NIH | 2/18/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,982,285 ) |
| | 2022 | 2022 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 000 | 4 | NIH | 7/26/2022 | $982,292 |
| | 2022 | 2022 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44HL156295 | CMC of Peptide Formulation for the Treatment of ARDS | 000 | 1 | NIH | 5/23/2022 | $999,993 |
|
| Issue Date FY: 2021 ( Subtotal = $992,469 ) |
| | 2021 | 2021 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 001 | 3 | NIH | 8/26/2021 | $0 |
| | 2021 | 2021 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 000 | 3 | NIH | 8/12/2021 | $992,469 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44HL134448 | Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP | 000 | 2 | NIH | 6/22/2020 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $999,596 ) |
| | 2018 | 2018 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44HL134448 | Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP | 000 | 2 | NIH | 3/22/2018 | $999,596 |
|
| Issue Date FY: 2017 ( Subtotal = $999,659 ) |
| | 2017 | 2017 | PHARMAIN CORPORATION | 19805 N CREEK PKWY STE 200 | BOTHELL | WA | 98011-8251 | KING | USA | R44HL134448 | Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP | 000 | 1 | NIH | 8/10/2017 | $999,661 |
| | 2017 | 2015 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R43AI107953 | Medical countermeasure after radiation exposure | 000 | 2 | NIH | 4/10/2017 | $0 |
| | 2017 | 2015 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R43DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 000 | 2 | NIH | 8/14/2017 | $0 |
| | 2017 | 2015 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R43AI107953 | Medical countermeasure after radiation exposure | 001 | 2 | NIH | 4/13/2017 | $0 |
| | 2017 | 2014 | PHARMAIN CORPORATION | 11812 N CREEK PARKWAY N STE 101 | BOTHELL | WA | 98011-8202 | KING | USA | R44DK084724 | EGF/Gastrin for Islet Regeneration | 000 | 4 | NIH | 12/8/2016 | -$2 |
|
| Issue Date FY: 2015 ( Subtotal = $580,128 ) |
| | 2015 | 2015 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 000 | 2 | NIH | 6/18/2015 | $280,313 |
| | 2015 | 2015 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI107953 | Medical countermeasure after radiation exposure | 000 | 2 | NIH | 2/4/2015 | $299,815 |
|
| Issue Date FY: 2014 ( Subtotal = $1,567,750 ) |
| | 2014 | 2014 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI107953 | Medical countermeasure after radiation exposure | 000 | 1 | NIH | 2/5/2014 | $299,872 |
| | 2014 | 2014 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AG042208 | Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder | 000 | 1 | NIH | 2/5/2014 | $225,000 |
| | 2014 | 2014 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43DK103553 | Subcutaneous Drug Development for Portal Hypertension Ascites | 000 | 1 | NIH | 9/19/2014 | $293,272 |
| | 2014 | 2014 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R44DK084724 | EGF/Gastrin for Islet Regeneration | 000 | 4 | NIH | 8/18/2014 | $749,606 |
|
| Issue Date FY: 2013 ( Subtotal = $1,239,243 ) |
| | 2013 | 2013 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R44DK084724 | EGF/Gastrin for Islet Regeneration | 000 | 3 | NIH | 9/5/2013 | $750,084 |
| | 2013 | 2013 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI098137 | VASOACTIVE INTESTINAL PEPTIDE FOR THE TREATMENT OF PSORIASIS | 000 | 2 | NIH | 8/8/2013 | $145,203 |
| | 2013 | 2013 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI098130 | NANOCARRIER FORMULATED ENZYME FOR THE TREATMENT OF S. AUREUS INFECTION | 000 | 2 | NIH | 4/8/2013 | $300,000 |
| | 2013 | 2013 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R44DK084724 | EGF/Gastrin for Islet Regeneration | 001 | 3 | NIH | 9/17/2013 | $43,956 |
|
| Issue Date FY: 2012 ( Subtotal = $826,738 ) |
| | 2012 | 2012 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI098130 | NANOCARRIER FORMULATED ENZYME FOR THE TREATMENT OF S. AUREUS INFECTION | 000 | 1 | NIH | 5/9/2012 | $300,000 |
| | 2012 | 2012 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI094664 | NANOCARRIER-FORMULATED NF-KB INHIBITORS FOR INFLAMMATORY DISEASES | 000 | 2 | NIH | 6/21/2012 | $299,973 |
| | 2012 | 2012 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI098137 | VASOACTIVE INTESTINAL PEPTIDE FOR THE TREATMENT OF PSORIASIS | 000 | 1 | NIH | 9/6/2012 | $226,765 |
|
| Issue Date FY: 2011 ( Subtotal = $732,280 ) |
| | 2011 | 2011 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43AI094664 | NANOCARRIER-FORMULATED NF-KB INHIBITORS FOR INFLAMMATORY DISEASES | 000 | 1 | NIH | 7/13/2011 | $299,976 |
| | 2011 | 2011 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R44AA019584 | NANOCARRIER-FORMULATED ANTI-FIBROTIC PEPTIDES FOR CIRRHOSIS - FAST TRACK SBIR | 000 | 3 | NIH | 7/8/2011 | $432,304 |
|
| Issue Date FY: 2010 ( Subtotal = $1,264,233 ) (Continued on the next page) |
| | 2010 | 2010 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R44AA019584 | NANOCARRIER-FORMULATED ANTI-FIBROTIC PEPTIDES FOR CIRRHOSIS - FAST TRACK SBIR | 000 | 1 | NIH | 3/29/2010 | $160,363 |
| | 2010 | 2010 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43DK084724 | EGF/GASTRIN FOR ISLET CELL REGENERATION | 001 | 2 | NIH | 9/6/2010 | $229,824 |
| | 2010 | 2010 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R43DK085754 | OUTPATIENT TREATMENT FOR PORTAL HYPERTENSION | 000 | 1 | NIH | 2/26/2010 | $223,422 |
| | 2010 | 2010 | PHARMAIN CORPORATION | 720 BROADWAY SUITE 511 | SEATTLE | WA | 98122-4302 | KING | USA | R44AA019584 | NANOCARRIER-FORMULATED ANTI-FIBROTIC PEPTIDES FOR CIRRHOSIS - FAST TRACK SBIR | 001 | 2 | NIH | 6/28/2010 | $350,624 |
|
